Answers are grounded in this paper and cite their sources.
Longitudinal evaluation reveals improved consistency of cerebrospinal fluid biomarker assays across laboratories, indicating effective international quality control initiatives.
Introduction: Cerebrospinal Fluid (CSF) biomarkers Total Tau Protein ( T ), Amyloid Beta Peptide (A 42 ) and tau protein hyper phosphorylated at threonine 181 ( P-181 ) are important in the (differential) diagnosis of dementia and analysis of these biomarkers is now incorporated in the diagnostic criteria of Alzheimer's disease. However, lack of standardization has led to considerable inter-and intra-laboratory variation. Various international programs have been launched aiming in the reduction of variability and harmonization of biomarker measurements.
No takes yet. Share an insight, caveat, or question.
A 2018 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: